ICON Public Limited (NASDAQ:ICLR) Receives Consensus Rating of “Moderate Buy” from Analysts

ICON Public Limited (NASDAQ:ICLR) has been given an average rating of “Moderate Buy” by the fifteen research firms that are currently covering the firm, Marketbeat reports. Four research analysts have rated the stock with a hold recommendation, ten have issued a buy recommendation and one has issued a strong buy recommendation on the company. The average 12 month price objective among analysts that have covered the stock in the last year is $272.50.

A number of research firms have recently issued reports on ICLR. Truist Financial reduced their price target on shares of ICON Public from $284.00 to $262.00 and set a “buy” rating on the stock in a research report on Thursday, February 13th. Royal Bank of Canada reissued an “outperform” rating and issued a $263.00 target price on shares of ICON Public in a report on Wednesday, January 15th. Citigroup lowered their target price on ICON Public from $300.00 to $290.00 and set a “buy” rating for the company in a report on Monday, January 6th. Robert W. Baird cut their price target on ICON Public from $221.00 to $203.00 and set a “neutral” rating on the stock in a report on Tuesday, March 4th. Finally, The Goldman Sachs Group downgraded ICON Public from a “buy” rating to a “neutral” rating and lowered their price objective for the stock from $250.00 to $200.00 in a research note on Friday.

Hedge Funds Weigh In On ICON Public

Several hedge funds have recently bought and sold shares of the business. Icon Wealth Advisors LLC boosted its stake in shares of ICON Public by 861.1% during the 3rd quarter. Icon Wealth Advisors LLC now owns 13,215 shares of the medical research company’s stock worth $3,797,000 after acquiring an additional 11,840 shares in the last quarter. Foyston Gordon & Payne Inc bought a new stake in ICON Public during the third quarter worth approximately $11,672,000. Tributary Capital Management LLC grew its holdings in ICON Public by 116.1% during the fourth quarter. Tributary Capital Management LLC now owns 3,950 shares of the medical research company’s stock valued at $828,000 after purchasing an additional 2,122 shares during the last quarter. GAMMA Investing LLC raised its position in shares of ICON Public by 64.0% in the fourth quarter. GAMMA Investing LLC now owns 433 shares of the medical research company’s stock valued at $91,000 after purchasing an additional 169 shares during the period. Finally, Entropy Technologies LP lifted its stake in shares of ICON Public by 472.2% in the fourth quarter. Entropy Technologies LP now owns 6,174 shares of the medical research company’s stock worth $1,295,000 after buying an additional 5,095 shares during the last quarter. 95.61% of the stock is owned by institutional investors and hedge funds.

ICON Public Trading Up 0.5 %

NASDAQ:ICLR opened at $184.87 on Tuesday. The business’s 50-day moving average is $192.76 and its two-hundred day moving average is $226.31. The firm has a market capitalization of $14.93 billion, a PE ratio of 19.40, a price-to-earnings-growth ratio of 1.86 and a beta of 1.21. ICON Public has a 12 month low of $174.93 and a 12 month high of $347.72. The company has a debt-to-equity ratio of 0.36, a current ratio of 1.26 and a quick ratio of 1.34.

ICON Public (NASDAQ:ICLR) last issued its quarterly earnings data on Wednesday, February 19th. The medical research company reported $3.42 EPS for the quarter, topping analysts’ consensus estimates of $3.41 by $0.01. ICON Public had a net margin of 9.56% and a return on equity of 11.81%. The firm had revenue of $2.04 billion for the quarter, compared to analyst estimates of $2.04 billion. Research analysts predict that ICON Public will post 13.38 earnings per share for the current fiscal year.

ICON Public Company Profile

ICON Public Limited Company, a clinical research organization, provides outsourced development and commercialization services in Ireland, rest of Europe, the United States, and internationally. The company specializes in the strategic development, management, and analysis of programs that support various stages of the clinical development process from compound selection to Phase I-IV clinical studies.